|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: RANBP3 |
Gene summary for RANBP3 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | RANBP3 | Gene ID | 8498 |
| Gene name | RAN binding protein 3 | |
| Gene Alias | RANBP3 | |
| Cytomap | 19p13.3 | |
| Gene Type | protein-coding | GO ID | GO:0006611 | UniProtAcc | B7Z7F3 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 8498 | RANBP3 | LZE4T | Human | Esophagus | ESCC | 1.05e-11 | 2.36e-01 | 0.0811 |
| 8498 | RANBP3 | LZE7T | Human | Esophagus | ESCC | 9.20e-15 | 5.83e-01 | 0.0667 |
| 8498 | RANBP3 | LZE8T | Human | Esophagus | ESCC | 2.41e-12 | 2.64e-01 | 0.067 |
| 8498 | RANBP3 | LZE20T | Human | Esophagus | ESCC | 1.87e-02 | 4.45e-02 | 0.0662 |
| 8498 | RANBP3 | LZE21D1 | Human | Esophagus | HGIN | 1.45e-03 | 2.00e-01 | 0.0632 |
| 8498 | RANBP3 | LZE22T | Human | Esophagus | ESCC | 2.41e-05 | 2.17e-01 | 0.068 |
| 8498 | RANBP3 | LZE24T | Human | Esophagus | ESCC | 6.60e-16 | 3.64e-01 | 0.0596 |
| 8498 | RANBP3 | LZE21T | Human | Esophagus | ESCC | 5.54e-08 | 2.36e-01 | 0.0655 |
| 8498 | RANBP3 | LZE6T | Human | Esophagus | ESCC | 5.48e-05 | 2.03e-01 | 0.0845 |
| 8498 | RANBP3 | P1T-E | Human | Esophagus | ESCC | 1.10e-06 | 3.52e-01 | 0.0875 |
| 8498 | RANBP3 | P2T-E | Human | Esophagus | ESCC | 1.70e-14 | 2.80e-01 | 0.1177 |
| 8498 | RANBP3 | P4T-E | Human | Esophagus | ESCC | 3.97e-17 | 3.57e-01 | 0.1323 |
| 8498 | RANBP3 | P5T-E | Human | Esophagus | ESCC | 7.16e-16 | 2.71e-01 | 0.1327 |
| 8498 | RANBP3 | P8T-E | Human | Esophagus | ESCC | 2.86e-20 | 4.27e-01 | 0.0889 |
| 8498 | RANBP3 | P9T-E | Human | Esophagus | ESCC | 5.53e-21 | 4.16e-01 | 0.1131 |
| 8498 | RANBP3 | P10T-E | Human | Esophagus | ESCC | 9.04e-21 | 4.36e-01 | 0.116 |
| 8498 | RANBP3 | P11T-E | Human | Esophagus | ESCC | 1.18e-18 | 4.63e-01 | 0.1426 |
| 8498 | RANBP3 | P12T-E | Human | Esophagus | ESCC | 2.71e-21 | 4.26e-01 | 0.1122 |
| 8498 | RANBP3 | P15T-E | Human | Esophagus | ESCC | 1.11e-12 | 2.88e-01 | 0.1149 |
| 8498 | RANBP3 | P16T-E | Human | Esophagus | ESCC | 5.07e-25 | 2.94e-01 | 0.1153 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000691319 | Esophagus | HGIN | nucleocytoplasmic transport | 83/2587 | 301/18723 | 2.14e-10 | 1.97e-08 | 83 |
| GO:005116919 | Esophagus | HGIN | nuclear transport | 83/2587 | 301/18723 | 2.14e-10 | 1.97e-08 | 83 |
| GO:005116819 | Esophagus | HGIN | nuclear export | 48/2587 | 154/18723 | 2.21e-08 | 1.34e-06 | 48 |
| GO:000661110 | Esophagus | HGIN | protein export from nucleus | 22/2587 | 57/18723 | 2.96e-06 | 1.02e-04 | 22 |
| GO:0006913110 | Esophagus | ESCC | nucleocytoplasmic transport | 230/8552 | 301/18723 | 6.04e-28 | 2.02e-25 | 230 |
| GO:0051169110 | Esophagus | ESCC | nuclear transport | 230/8552 | 301/18723 | 6.04e-28 | 2.02e-25 | 230 |
| GO:0051168110 | Esophagus | ESCC | nuclear export | 126/8552 | 154/18723 | 1.88e-20 | 2.65e-18 | 126 |
| GO:000661117 | Esophagus | ESCC | protein export from nucleus | 48/8552 | 57/18723 | 1.92e-09 | 4.39e-08 | 48 |
| GO:000691317 | Oral cavity | OSCC | nucleocytoplasmic transport | 204/7305 | 301/18723 | 2.65e-24 | 6.98e-22 | 204 |
| GO:005116917 | Oral cavity | OSCC | nuclear transport | 204/7305 | 301/18723 | 2.65e-24 | 6.98e-22 | 204 |
| GO:005116817 | Oral cavity | OSCC | nuclear export | 112/7305 | 154/18723 | 1.70e-17 | 1.56e-15 | 112 |
| GO:00066119 | Oral cavity | OSCC | protein export from nucleus | 42/7305 | 57/18723 | 1.10e-07 | 1.87e-06 | 42 |
| GO:000691324 | Skin | cSCC | nucleocytoplasmic transport | 162/4864 | 301/18723 | 4.20e-25 | 1.10e-22 | 162 |
| GO:005116924 | Skin | cSCC | nuclear transport | 162/4864 | 301/18723 | 4.20e-25 | 1.10e-22 | 162 |
| GO:0051168111 | Skin | cSCC | nuclear export | 91/4864 | 154/18723 | 3.33e-18 | 4.18e-16 | 91 |
| GO:000661119 | Skin | cSCC | protein export from nucleus | 34/4864 | 57/18723 | 8.07e-08 | 1.96e-06 | 34 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0516639 | Esophagus | HGIN | Human T-cell leukemia virus 1 infection | 51/1383 | 222/8465 | 5.84e-03 | 4.05e-02 | 3.22e-02 | 51 |
| hsa05166114 | Esophagus | HGIN | Human T-cell leukemia virus 1 infection | 51/1383 | 222/8465 | 5.84e-03 | 4.05e-02 | 3.22e-02 | 51 |
| hsa05166211 | Esophagus | ESCC | Human T-cell leukemia virus 1 infection | 164/4205 | 222/8465 | 8.13e-14 | 2.09e-12 | 1.07e-12 | 164 |
| hsa05166310 | Esophagus | ESCC | Human T-cell leukemia virus 1 infection | 164/4205 | 222/8465 | 8.13e-14 | 2.09e-12 | 1.07e-12 | 164 |
| hsa0516630 | Oral cavity | OSCC | Human T-cell leukemia virus 1 infection | 150/3704 | 222/8465 | 3.68e-13 | 7.26e-12 | 3.70e-12 | 150 |
| hsa05166113 | Oral cavity | OSCC | Human T-cell leukemia virus 1 infection | 150/3704 | 222/8465 | 3.68e-13 | 7.26e-12 | 3.70e-12 | 150 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| RANBP3 | SNV | Missense_Mutation | rs201812693 | c.763N>A | p.Ala255Thr | p.A255T | Q9H6Z4 | protein_coding | tolerated(0.61) | benign(0.015) | TCGA-BH-A0HA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| RANBP3 | SNV | Missense_Mutation | c.861C>G | p.His287Gln | p.H287Q | Q9H6Z4 | protein_coding | tolerated(0.65) | benign(0.001) | TCGA-C8-A12U-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| RANBP3 | SNV | Missense_Mutation | c.1255G>T | p.Val419Leu | p.V419L | Q9H6Z4 | protein_coding | tolerated(0.06) | possibly_damaging(0.593) | TCGA-EW-A1J2-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | SD | |
| RANBP3 | SNV | Missense_Mutation | novel | c.269N>C | p.Arg90Pro | p.R90P | Q9H6Z4 | protein_coding | deleterious_low_confidence(0.02) | benign(0.162) | TCGA-PL-A8LV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| RANBP3 | SNV | Missense_Mutation | c.733G>C | p.Glu245Gln | p.E245Q | Q9H6Z4 | protein_coding | tolerated(0.09) | benign(0.118) | TCGA-EK-A3GK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| RANBP3 | SNV | Missense_Mutation | rs748947507 | c.215N>T | p.Ser72Leu | p.S72L | Q9H6Z4 | protein_coding | tolerated_low_confidence(0.09) | benign(0) | TCGA-VS-A9UC-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
| RANBP3 | SNV | Missense_Mutation | rs753525599 | c.1144N>T | p.Arg382Trp | p.R382W | Q9H6Z4 | protein_coding | tolerated(0.1) | benign(0.01) | TCGA-A6-2672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| RANBP3 | SNV | Missense_Mutation | c.1103N>T | p.Ser368Phe | p.S368F | Q9H6Z4 | protein_coding | deleterious(0) | probably_damaging(0.987) | TCGA-A6-6138-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| RANBP3 | SNV | Missense_Mutation | rs749250391 | c.1123G>A | p.Ala375Thr | p.A375T | Q9H6Z4 | protein_coding | deleterious(0.02) | possibly_damaging(0.526) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
| RANBP3 | SNV | Missense_Mutation | c.343N>C | p.Tyr115His | p.Y115H | Q9H6Z4 | protein_coding | tolerated_low_confidence(0.12) | possibly_damaging(0.713) | TCGA-AA-A02O-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |